Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies - An expert consensus statement using a modified Delphi approach

Sep 29, 2026

Uploaded by Patrick

Liraglutide, semaglutide, and tirzepatide have reshaped obesity management, yet dose-related gastrointestinal effects, obesity-associated nutritional inadequacies, and poor long-term adherence can limit sustained health benefits. This expert consensus addresses that evidence gap by formulating nutrition and lifestyle supportive care priorities for glucagon-like peptide 1-based therapies (GBTs).

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Background

Methods

Results

Conclusions

Obesity Pillars 17 (2026) 100228 Contents lists available at ScienceDirect Obesity Pillars journal [homepage:](homepage: www.journals.elsevier.com/obesity-pillars)[ www.journals.elsevier.com/obesity-pillars](homepage: www.journals.elsevier.com/obesity-pillars) Review Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 -based therapies: An expert consensus statement using a modified Delphi approach J.L. Sievenpiper a,r,s,* , J. Ard b, M. Blüherc , W. Chend, J.B. Dixon e , A. Fitch f, L. Gigliotti g , K. Khuntih, A. Lecube i,j, M.E.J. Lean k, B. Mittendorfer l, A.F.H. Pfeiffer m, D.H. Ryan n , T. Vilsbøll o,p, L.F. Van Gaal q,** a Departments of Nutritional Sciences and Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada b Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA c Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany d Department of Clinical Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuai fu yuan Wang fu jing, Dong Cheng District, Beijing, 100730, China e Iverson Health Innovation Research Institute, Swinburne University of Technology, Melbourne, Australia f knownwell Health, Boston, MA, USA g Irvine, CA, USA h Diabetes Research Centre, University of Leicester, Leicester, UK i Endocrinology and Nutrition Department, Vall d’Hebron University Hospital, VHIR, Barcelona, Spain j Centro de Investigaci´on Biom´edica en Red de Diabetes y Enfermedades Metab´olicas Asociadas (CIBERDEM), Madrid, Spain k Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK l Departments of Medicine and Nutrition & Exercise Physiology, University of Missouri School of Medicine, Columbia, MO, USA m Charit´e-Universit¨atsmedizin Berlin, Klinik für Endokrinologie, Stoffwechsel-und Ern¨ahrungsmedizin, Berlin, Germany n Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA o Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark p Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark q Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium r Division of Endocrinology and Metabolism, Department of Medicine, St. Michael’s Hospital, Toronto, ON, Canada s Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada A R T I C L E I N F O Keywords: Liraglutide Nutrition Physical activity Semaglutide Tirzepatide Weight management A B S T R A C T Background: Liraglutide, semaglutide and tirzepatide have transformed the management of obesity. However, dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence may limit their long-term health benefits. Despite a recent joint advisory summarizing nutritional and lifestyle supportive care priorities with these therapies, there is still a significant lack of direct evidence to guide clinical practice, making consensus-based recommendations necessary. Methods: The consensus statement development was based on an initial scoping review that included searching PubMed, Embase, Web of Science, Cochrane, and Medline for relevant scientific publications from January 1, 2021 through June 30, 2025. An international multidisciplinary panel consisting of physicians, clinical researchers, and dietitians employed a modified Delphi process to develop clinical practice recommendations for nutritional and lifestyle strategies that may assist people on glucagon-like peptide 1 based

FAQs

Why are supportive nutritional and lifestyle recommendations needed for GLP-1-based obesity therapies?

Dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and challenges with long-term adherence may limit the long-term benefits of GLP-1-based treatments, creating a need for structured supportive care guidance.

How was the expert consensus statement developed?

The statement was developed using a modified Delphi approach by an international multidisciplinary panel, following an initial scoping review of relevant literature.

Which GLP-1-based therapies are addressed in the recommendations?

The document focuses on liraglutide, semaglutide, and tirzepatide as therapies used in obesity management within the GLP-1-based treatment framework.

Sep 29, 2026

Uploaded by Patrick